Sizzling market heats up biotech buyout fever

Biotech buyouts are all the rage these days. Following fast on the heels of yesterday's news that Gloucester is being bought out by Celgene, Merrimack Pharmaceuticals announced its deal to buy South San Francisco-based Hermes Biosciences. And Biogen Idec continues to press development partner Facet Biotech to accept its offer.


Post a Comment